Trivium Point Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Trivium Point Advisory’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.4M	Buy	+65,945	New	+$8.91M	0.95%	22
2025 Q1	–	Sell	-28,429	Closed	-$2.56M	–	355
2024 Q4	$2.56M	Sell	28,429 -44,602	-61%	-$4.32M	0.32%	90
2024 Q3	$7.3M	Buy	73,031 +8,854	+14%	+$870K	1.02%	20
2024 Q2	$5.95M	Buy	64,177 +60,002	+1,437%	+$5.38M	0.89%	25
2024 Q1	$396K	Buy	+4,175	New	+$387K	0.09%	174

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Trivium Point Advisory's XBI Position: Q2 2026 in Review

Trivium Point Advisory opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 65,945 shares worth $10.4M. The stake represents 0.95% of the portfolio and ranks #22 among its holdings. This is a return to the name: Trivium Point Advisory previously reported a position in XBI as recently as Q4 2024.

Trivium Point Advisory first reported a position in XBI in Q1 2024 and has held it in 5 quarters since. 933 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Trivium Point Advisory held 65,945 shares of State Street SPDR S&P Biotech ETF worth $10.4M as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Trivium Point Advisory position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.95% of Trivium Point Advisory's portfolio in Q2 2026, its #22 holding.
Trivium Point Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q1 2024 and has held it in 5 quarters since.
933 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Trivium Point Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.